NCTId;BriefTitle;HasResults;type;doi;pmid;published_date
NCT02592174;Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study;False;DERIVED;10.1093/cid/ciz670;31755936;2019-07-25
NCT02273765;Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;False;DERIVED;10.1016/S1473-3099(20)30869-0;33667406;2021-06-01
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;False;PUBMED;10.3389/fpubh.2022.981213;36438274;2022-11-04
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;False;PUBMED;10.1093/cid/ciad603;37795682;2023-10-05
NCT02107365;Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO);False;;;;
NCT02099474;Evaluation of Raltegravir During the Third Trimester of Pregnancy;False;DERIVED;10.1128/AAC.00759-20;32661003;2020-09-21
NCT02116374;Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients;False;;;;
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.1001/jama.2020.6887;32338732;2020-06-02
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.1056/NEJMoa2002032;32109013;2020-04-30
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.2807/1560-7917.ES.2020.25.5.2000062;32046819;2020-02-06
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.2807/1560-7917.ES.2020.25.6.2000094;32070465;2020-02-13
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.1056/NEJMoa2001316;31995857;2020-03-26
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.1056/NEJMoa2001017;31978945;2020-02-20
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.1016/j.ijantimicag.2020.106006;32371096;2020-06-01
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;False;SUSPICIOUS;10.1016/S1473-3099(20)30200-0;32224310;2020-06-01
NCT01620957;Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma;False;;;;
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1016/j.vaccine.2008.08.018;18762220;2008-10-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.4049/jimmunol.1003765;21430219;2011-05-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;DERIVED;10.1172/JCI135020;31945015;2020-03-23
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1128/CVI.00322-09;20107007;2010-03-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1016/j.vaccine.2010.08.017;20708998;2010-10-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1371/journal.pone.0083449;24421886;2014-01-08
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1128/CVI.00082-09;19625486;2009-09-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1016/j.vaccine.2012.07.005;22814407;2012-08-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1128/CVI.00371-10;21147936;2011-02-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;DERIVED;10.1016/S1473-3099(20)30274-7;32687804;2020-11-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1016/j.vaccine.2014.04.048;24793938;2014-06-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1371/journal.pone.0010178;20419113;2010-04-15
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;True;BACKGROUND;10.1016/j.vaccine.2014.06.019;24950361;2014-07-01
NCT02497274;Obesity and Lipids: a Matter of Taste?;False;;;;
NCT02987530;National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection;False;;;;
NCT03446430;Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients;False;;;;
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;BACKGROUND;10.1016/j.ajog.2007.03.003;17825642;2007-09-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1097/MD.0000000000022352;32991450;2020-09-25
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1186/1471-2334-12-246;23039034;2012-10-06
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1093/cid/ciaa161;32067040;2020-02-18
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1111/eos.12669;31994250;2020-01-29
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1016/S2352-3018(18)30361-8;30814028;2019-05-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1016/S0140-6736(15)00984-8;26603917;2016-02-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1186/s13006-017-0112-2;28469697;2016-12-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1093/cid/ciz888;31633158;2019-10-21
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1186/s12889-020-08564-1;32228542;2020-03-30
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;PUBMED;10.1186/s12955-021-01844-3;34425825;2021-08-23
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;False;DERIVED;10.1128/AAC.01869-16;27895016;2017-02-01
NCT05040048;Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease;False;;;;
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;False;DERIVED;10.1016/S2468-2667(17)30211-6;29307383;2018-01-01
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;False;DERIVED;10.1136/jech-2017-209739;29437866;2018-02-02
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;False;DERIVED;10.1093/eurpub/cky118;29982518;2018-07-02
NCT02073630;Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia;False;;;;
NCT01693848;"""Cancersensor"" Metastasis Resection";False;;;;
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;DERIVED;10.1136/jmedgenet-2013-102200;24780882;2014-04-29
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1136/jmg.2006.046425;17098887;2007-04-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;DERIVED;10.1001/archneurol.2011.2713;22491195;2012-04-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;SUSPICIOUS;10.1212/01.wnl.0000137020.30604.1e;15365159;2004-09-14
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;SUSPICIOUS;10.1001/archneur.61.8.1242;15313841;2004-08-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1007/s00439-007-0396-1;17605047;2007-06-28
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1038/ng1758;16501573;2006-02-26
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1002/ana.20628;16193476;2005-09-28
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1038/sj.ejhg.5201922;17957230;2007-10-24
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1093/brain/awn059;18378516;2008-03-31
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1002/humu.20920;18853458;2009-02-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1007/s10048-007-0090-4;17597328;2007-06-28
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;False;RESULT;10.1136/jmg.2005.035311;16055926;2005-08-23
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1111/bcp.15669;36680782;2023-02-08
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;DERIVED;10.1016/S0140-6736(22)00519-0;35512728;2022-05-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;DERIVED;10.1002/14651858.CD013825.pub2;34473343;2021-09-02
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1016/S1473-3099(22)00295-X;35643099;2022-06-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1016/j.cmi.2022.04.016;35533972;2022-09-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1002/prp2.1072;37269068;2023-06-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;DERIVED;10.1016/S2213-2600(20)30172-7;32304640;2020-06-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1016/j.cmi.2021.05.020;34048876;2021-12-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1016/S1473-3099(21)00485-0;34534511;2022-02-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1093/jac/dkaa415;33089306;2020-10-22
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1093/jac/dkac048;35233617;2022-03-02
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;DERIVED;10.1002/14651858.CD014962;34350582;2021-08-05
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1016/S2213-2600(22)00528-8;36828006;2023-05-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1056/NEJMoa2023184;33264556;2021-02-11
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;RESULT;10.1002/psp4.13051;37728045;2023-10-11
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1136/bmjopen-2020-041437;32958495;2020-09-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1016/j.cmi.2022.05.005;35623577;2022-09-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;PUBMED;10.1093/cid/ciae170;38552208;2024-03-29
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1016/j.cct.2023.107267;37302469;2023-08-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1016/j.cmi.2021.10.011;34763056;2022-01-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;PUBMED;10.1002/14651858.CD014962.pub2;36695483;2023-01-25
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;False;BACKGROUND;10.1093/jac/dkaa191;32473020;2020-05-30
NCT03298360;A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a;False;;;;
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);False;DERIVED;10.1371/journal.pone.0180191;28708873;2017-07-14
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);False;DERIVED;10.1016/S1473-3099(15)70021-6;25701561;2015-04-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.1017/S0950268816002934;28004616;2016-12-22
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;DERIVED;10.1093/ofid/ofac181;35774932;2022-04-14
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.1177/00333549161310S214;27168667;2016-05-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.1016/j.cmi.2016.01.009;26806260;2016-05-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.1080/09540121.2016.1178698;27178119;2016-05-13
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.7326/M16-0816;27537841;2016-08-09
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.1097/MLR.0b013e3182408812;22310560;2012-03-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;False;BACKGROUND;10.1016/j.drugalcdep.2017.11.033;29432973;2018-04-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;False;DERIVED;10.3945/ajcn.114.085720;24808487;2014-07-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;False;DERIVED;10.3945/jn.115.212837;26063065;2015-08-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;False;BACKGROUND;10.1002/mnfr.201100322;21957063;2012-02-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;False;DERIVED;10.3945/jn.116.237115;27798339;2016-12-01
NCT02078076;IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère;False;;;;
NCT03546127;Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study;False;;;;
NCT02014727;Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults;False;DERIVED;10.1016/j.vaccine.2017.09.027;28947345;2017-10-01
NCT02650427;A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection;False;;;;
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;RESULT;10.1080/09540121.2016.1178698;27178119;2016-05-13
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;RESULT;10.1016/j.drugpo.2016.02.021;27006257;2016-06-01
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;BACKGROUND;10.1007/s10461-015-1113-z;26080690;2015-06-17
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;RESULT;10.1016/j.drugalcdep.2017.07.004;28800503;2017-10-01
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;BACKGROUND;10.1111/add.12999;26032121;2015-07-14
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;BACKGROUND;10.3109/10826084.2015.978185;25540950;2014-12-26
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;RESULT;10.1007/s10461-017-1814-6;28612212;2017-06-13
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;BACKGROUND;10.1016/j.drugpo.2015.04.015;26050614;2015-11-01
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;True;BACKGROUND;10.1080/10550887.2015.1059111;26075647;2015-06-15
NCT03459157;Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP);False;DERIVED;10.1016/S2352-3018(21)00005-9;34048794;2021-07-01
NCT01895920;Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?;False;;;;
NCT04808986;Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts;False;;;;
NCT03078439;EPIPAGE2 Cohort Study Follow up at Five and a Half Years;False;PUBMED;10.1136/archdischild-2023-326336;38408861;2024-02-26
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;False;DERIVED;10.1136/sextrans-2020-054755;33753460;2021-03-22
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;False;DERIVED;10.1097/QAD.0000000000003046;34352834;2021-08-04
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;False;DERIVED;10.1186/s12889-021-10994-4;34022820;2021-05-22
NCT00670839;Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST);False;DERIVED;10.1016/S1473-3099(15)00220-0;26257021;2015-11-01
NCT01693835;"""Cancersensor"": Circadian Rhythms";False;;;;
NCT01493934;Development of a Fast Measurement Technique of Insulin Resistance in Human;False;;;;
NCT02428816;Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes;False;;;;
NCT02886416;Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity;False;;;;
NCT02267304;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic);False;;;;
NCT02073604;Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm;False;;;;
NCT03047967;Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns;False;;;;
NCT04484740;Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue;False;;;;
NCT03642704;HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure;False;;;;
NCT00323804;Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.;False;;;;
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;False;DERIVED;10.1016/S1473-3099(17)30725-9;29229440;2018-03-01
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;False;PUBMED;10.1136/sextrans-2022-055634;36601747;2022-12-08
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;False;DERIVED;10.1016/S2352-3018(19)30341-8;31784343;2020-02-01
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;False;DERIVED;10.1056/NEJMoa1506273;26624850;2015-12-03
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;False;DERIVED;10.1016/S2352-3018(17)30089-9;28747274;2017-09-01
NCT01525472;Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects;False;;;;
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.7448/IAS.20.01.21362;28453240;2017-01-01
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.1097/QAD.0000000000003043;34723858;2021-11-15
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.1128/AAC.00297-17;28483965;2017-07-01
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.1111/bcp.13397;28800382;2017-09-20
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.1186/s12916-017-0842-4;28434406;2017-04-24
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.1093/ofid/ofz276;31334298;2019-06-11
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;False;DERIVED;10.7448/IAS.19.1.20601;27015798;2016-01-01
NCT02384967;Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients;False;DERIVED;10.1093/jac/dky193;29905808;2018-06-13
NCT04849767;National Survey About Trajectory and Life Conditions of HIV Trans People in France;False;DERIVED;10.1136/bmjopen-2021-052691;34916316;2021-12-01
NCT03109067;Genetic and Metabolism of Post-prandial HDL Particles;False;;;;
NCT01332955;Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen;False;DERIVED;10.1093/cid/ciu659;25139963;2014-08-18
NCT01703962;Non Invasive IDentification of Gliomas With IDH1 Mutation;False;PUBMED;10.1148/radiol.223255;37668523;2023-09-01
NCT01882062;Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease;True;RESULT;10.1212/WNL.0000000000001214;25568297;2015-02-03
NCT05349162;Epicardial vs. Transvenous ICDs in Children;False;PUBMED;10.1093/europace/euad015;36735263;2023-02-03
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;False;SUSPICIOUS;10.1016/j.placenta.2007.03.008;17531315;2007-10-01
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;False;SUSPICIOUS;10.1210/en.2005-0912;16384869;2006-04-01
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;False;SUSPICIOUS;10.1111/j.1582-4934.2008.00554.x;19602057;2008-10-16
NCT01335529;Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin;False;DERIVED;10.1080/15284336.2015.1135553;27077673;2016-02-11
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;False;DERIVED;10.1177/0379572116679053;27881690;2016-11-23
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;False;DERIVED;10.1186/s12879-018-3282-7;30081838;2018-08-06
NCT04780191;Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke;False;BACKGROUND;10.1186/s42234-019-0028-9;32232101;2019-07-23
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;False;DERIVED;10.2196/32007;34874888;2021-12-06
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;False;DERIVED;10.1186/s13063-016-1511-1;27488181;2016-08-03
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;False;DERIVED;10.1016/S2352-3018(15)00181-2;26520926;2015-11-01
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;False;DERIVED;10.1016/S0140-6736(14)61170-3;25103176;2014-11-01
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;False;DERIVED;10.1097/QAI.0000000000001834;30365452;2018-12-01
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;False;DERIVED;10.1016/S2352-3018(21)00006-0;33794182;2021-04-01
NCT01508494;Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment;False;;;;
NCT01453192;Renal Transplantation and Raltegravir in HIV-Infected Patients;False;PUBMED;10.1111/hiv.12700;30688008;2019-01-27
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1002/gps.755;12461757;2002-10-23
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1080/02699050500443467;16421064;2006-01-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1007/s00415-006-7012-5;17131230;2006-12-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1159/000051206;10436334;1999-01-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1212/WNL.0b013e3181c34b34;19933975;2009-11-24
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1176/jnp.3.3.243;1821241;1991-08-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1037/a0025318;21895376;2012-01-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1097/00005053-199404000-00008;10678322;1994-04-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1136/jnnp.2003.033258;15897497;2005-06-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1093/cercor/bhj043;16207933;2005-10-05
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1161/STROKEAHA.109.554410;19713543;2009-10-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1016/j.brainresbull.2006.06.007;17027767;2006-10-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1002/mds.21968;18307266;2008-04-24
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1016/s0166-2236(00)01626-x;10941190;2000-09-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;False;BACKGROUND;10.1080/09602010902949207;19533496;2009-08-01
NCT00658346;Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon;False;DERIVED;10.1093/cid/ciz371;31063537;2019-05-07
NCT01226446;Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders;False;DERIVED;10.3748/wjg.v21.i18.5647;25987791;2015-01-01
NCT04133012;Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone;False;;;;
NCT05199831;Situational Analysis of HIV-related Disability in the Context of Ivory Coast;False;;;;
NCT02486731;Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes;False;;;;
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;False;DERIVED;10.1007/s40273-020-00987-3;33355914;2020-12-23
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;False;DERIVED;10.1056/NEJMoa1904340;31339676;2019-08-29
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;False;DERIVED;10.1016/S2352-3018(20)30238-1;33010241;2020-10-01
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;False;PUBMED;10.1093/ofid/ofad582;38156046;2023-11-20
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;False;PUBMED;10.1097/QAI.0000000000003273;37851566;2023-11-01
NCT03671291;Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV;False;;;;
NCT01552044;Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis;False;;;;
NCT02542800;The Influence of Collective Schemas on Individual Memory;False;;;;
NCT02992184;PoC-HCV Genedrive Viral Detection Assay Validation Study;False;DERIVED;10.1136/gutjnl-2017-315783;29615488;2018-04-03
NCT01605890;Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients;True;DERIVED;10.1093/cid/ciy245;29590335;2018-03-24
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1093/infdis/jit149;23559464;2013-04-04
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1093/cid/civ578;26197844;2015-07-21
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1093/jac/dkr504;22160145;2011-12-07
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1093/cid/cit390;23766338;2013-06-12
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1111/hiv.12348;26709605;2015-12-28
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1371/journal.pone.0041390;22848481;2012-07-25
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;False;BACKGROUND;10.1097/QAD.0000000000001051;26854809;2016-05-15
NCT02126384;Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response;False;;;;
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;False;SUSPICIOUS;10.1046/j.1472-8206.2003.00152.x;12914551;2003-07-07
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;False;SUSPICIOUS;10.1212/01.wnl.0000132840.40838.13;15249613;2004-07-13
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;False;SUSPICIOUS;10.1111/j.1365-2125.1990.tb03848.x;2271377;1990-11-01
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;False;SUSPICIOUS;10.1038/sj.bjp.0705737;15037514;2004-05-01
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;False;SUSPICIOUS;10.1016/j.eplepsyres.2005.02.002;15777732;2005-02-01
NCT02212379;Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL;True;PUBMED;10.1093/jac/dkz224;31269208;2019-07-03
NCT02071784;Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL);False;;;;
NCT01696708;Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease;False;DERIVED;10.1212/WNL.0000000000001214;25568297;2015-02-03
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1093/cid/cix015;28329393;2017-03-13
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1186/1745-6215-14-230;23880306;2013-01-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1016/S2352-3018(17)30205-9;29199100;2018-03-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1186/s12889-015-1344-y;25880823;2015-03-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1002/jia2.25112;29890048;2018-06-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1002/jia2.25128;30027600;2018-07-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1371/journal.pmed.1002107;27504637;2016-08-09
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1093/cid/ciy881;30321314;2018-10-15
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1371/journal.pone.0239513;32970730;2020-09-24
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1002/jia2.25402;31637821;2019-10-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;False;DERIVED;10.1371/journal.pone.0202473;30412926;2018-11-09
NCT02314208;Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5;False;;;;
NCT01348308;Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients;False;DERIVED;10.7326/M19-2133;32040959;2020-02-11
NCT02323308;Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination;False;;;;
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;False;DERIVED;10.1093/cid/ciy382;29767684;2018-05-15
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;False;DERIVED;10.1007/s41669-019-0130-7;30968368;2019-04-09
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;False;SUSPICIOUS;10.1111/j.1460-9568.2012.08079.x;22639796;2012-05-28
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;False;SUSPICIOUS;10.1016/j.neuroscience.2013.07.047;23916713;2013-11-01
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;False;SUSPICIOUS;10.1146/annurev.ne.03.030180.001201;6774653;1980-03-01
NCT03335995;Stroke Prognosis in Intensive CarE;False;PUBMED;10.1161/STROKEAHA.123.042910;37497675;2023-09-01
NCT03335995;Stroke Prognosis in Intensive CarE;False;DERIVED;10.1007/s12028-019-00907-0;32026446;2020-02-05
NCT01647295;Social Interactions: Ocular Explorations and Pupillometry in Autism;False;;;;
NCT04824638;BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers;False;;;;
NCT01874808;From Movement Preparation to Gait Execution in ALS;False;;;;
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;False;BACKGROUND;10.1016/j.cct.2021.106402;33872801;2021-06-01
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;False;BACKGROUND;10.1016/S0140-6736(15)00984-8;26603917;2016-02-01
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;False;PUBMED;10.1016/S0140-6736(23)02464-9;38484756;2024-04-01
NCT01942655;IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection;False;;;;
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;False;BACKGROUND;10.1097/QAI.0b013e318221c56a;21602695;2011-08-01
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;False;BACKGROUND;10.1126/scitranslmed.3003327;22814853;2012-07-18
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;False;BACKGROUND;10.1016/S0140-6736(15)00984-8;26603917;2016-02-01
NCT02113943;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation;False;;;;
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;False;DERIVED;10.1097/QAD.0000000000001963;30096071;2018-10-23
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;False;PUBMED;10.1016/j.vaccine.2015.08.055;26314624;2015-10-01
NCT03150290;Brown Adipose Tissue in ALS;False;;;;
NCT03652090;Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis;False;;;;
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;False;DERIVED;10.1016/j.jhep.2013.04.035;23669289;2013-09-01
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;False;DERIVED;10.1111/liv.12759;25556540;2015-01-23
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;False;DERIVED;10.1053/j.gastro.2014.03.051;24704719;2014-07-01
NCT04945655;Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability;False;DERIVED;10.1136/bmjopen-2021-057943;35332045;2022-03-01
NCT04945655;Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability;False;PUBMED;10.1001/jamanetworkopen.2024.11938;38780943;2024-05-23
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;False;BACKGROUND;10.1016/j.respe.2010.10.008;21256688;2011-02-01
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;False;DERIVED;10.1016/j.jval.2017.09.020;29909873;2018-06-01
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;False;DERIVED;10.1016/j.ypmed.2017.08.012;28823681;2017-10-01
NCT02469350;Serious Game for Parkinson's Disease Patients;False;DERIVED;10.1186/s12984-018-0375-x;29636105;2018-04-10
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1097/ICB.0000000000000701;29369084;2018-01-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1001/jamaophthalmol.2015.1132;25997175;2015-08-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1016/j.preteyeres.2018.07.001;30010022;2018-09-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1097/HJH.0000000000000894;27065002;2016-06-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1016/j.ophtha.2013.12.036;24576889;2014-06-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1530/EJE-19-0390;31972545;2020-03-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1097/IAE.0000000000002738;31922497;2020-01-07
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1097/IAE.0000000000000269;25077537;2015-01-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1097/HJH.0000000000000095;24406779;2014-04-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1038/hr.2016.26;27009576;2016-03-24
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1007/s10633-017-9612-z;28900746;2017-09-12
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1016/j.ajo.2014.09.043;25284764;2015-01-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1007/s10633-013-9421-y;24337723;2013-12-13
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1007/s00417-015-3136-6;26344727;2015-09-07
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1167/iovs.15-17022;26523388;2015-11-02
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1080/09273948.2019.1646773;31573376;2019-10-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1167/iovs.12-10672;23620431;2013-04-25
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;DERIVED;10.1097/IAE.0000000000000737;26418443;2016-03-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1016/j.ejca.2019.02.015;30947025;2019-05-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;False;RESULT;10.1097/IAE.0000000000002648;31568064;2020-08-01
NCT01952587;X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study;False;;;;
NCT00928187;Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé);True;DERIVED;10.1007/s41669-019-0157-9;31273686;2019-07-04
NCT06260319;Decoding Developmental Disorders in Humams;False;;;;
NCT01842919;Dance and Huntington Disease;False;;;;
NCT01713335;Proteasis Evaluation in COPD;False;;;;
NCT01579435;Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation;False;;;;
NCT04684758;HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study;False;;;;
NCT02192658;Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa;False;DERIVED;10.1136/bmjopen-2015-008934;26846895;2016-02-01
NCT04631224;Longitudinal Analysis of Oral Communication in Friedreich's Ataxia;False;;;;
NCT00604149;Cardiac AResT And GENEtic;False;;;;
NCT01569399;Efficacity of rTMS in Alcohol Dependance;False;;;;
NCT03193099;Decoding Presymptomatic White Matter Changes in Huntington Disease;False;;;;
NCT01164436;Cohort of HIV Associated Lymphomas;False;;;;
NCT02051413;Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN);False;;;;
NCT01779713;Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage;False;DERIVED;10.1161/STROKEAHA.118.021101;30354977;2018-09-01
NCT01899196;Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients;False;;;;
NCT02038842;Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers;False;;;;
NCT02978924;Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor;False;;;;
NCT02160119;Emotional and Change-related Attention in Autism;False;;;;
NCT01592175;Magnetoencephalography (MEG), Attention and Conscience;False;;;;
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1086/653674;20536367;2010-07-15
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1097/QAD.0b013e3282f88d02;18614870;2008-07-31
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1097/QAD.0b013e32834d614c;21971357;2011-11-28
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1097/INF.0000000000000450;24945880;2014-12-01
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1093/cid/cit729;24253249;2013-11-18
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1093/cid/cir950;22198788;2011-12-23
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1016/S0140-6736(11)60208-0;21511330;2011-05-01
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1086/521165;17712765;2007-09-15
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1016/S2352-3018(15)00232-5;26762993;2016-01-01
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1093/infdis/jis233;22427678;2012-03-15
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1371/journal.pone.0093554;24705410;2014-04-03
NCT03235258;Cohort of HIV-infected Children;False;RESULT;10.1097/QAD.0b013e328326ca37;19194272;2009-03-13
NCT02527096;A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol);False;;;;
NCT03071458;Mutational Landscape in Hepatocellular Carcinoma;False;;;;
NCT02405013;Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa;False;PUBMED;10.1016/j.jhepr.2022.100665;36686592;2023-03-01
NCT04265742;Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture;False;;;;
NCT00265642;Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C;False;;;;
NCT01725542;Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders;False;DERIVED;10.1093/cid/civ381;25977266;2015-05-14
NCT01801618;National Evaluation of PI-based 2nd Line Efficacy in Cambodia;False;PUBMED;10.3389/fpubh.2018.00063;29662875;2018-03-19
NCT01207986;Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study;False;;;;
NCT02081066;Identification of CETP as a Marker of Atherosclerosis;False;;;;
NCT01022476;Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients;False;;;;
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;False;PUBMED;10.1093/cid/ciad125;36883573;2023-03-08
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;False;DERIVED;10.1056/NEJMoa1910708;32558469;2020-06-18
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1056/NEJMra1213651;23675659;2013-05-16
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1002/hep.26141;23172780;2013-02-04
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1111/j.1365-2893.2010.01278.x;20196807;2010-12-10
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/j.jhep.2015.02.006;25920094;2015-04-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1007/s11524-009-9417-9;20041309;2009-12-30
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1002/hep.26431;23553643;2013-08-26
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1111/j.1440-1746.2011.06974.x;22098550;2012-01-20
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/j.jhep.2016.06.015;27349488;2016-10-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1002/jmv.21787;20572071;2010-06-22
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1371/journal.pone.0153744;27148964;2016-05-05
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/j.drugpo.2015.07.004;26298331;2015-10-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/j.drugpo.2014.08.014;25245939;2015-02-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1111/j.1360-0443.2012.03932.x;22564041;2012-07-12
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1093/cid/cit377;23728143;2013-05-31
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1080/09540121.2016.1178698;27178119;2016-05-13
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1093/cid/cit296;23884064;2013-08-15
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/j.jhep.2014.07.027;25086286;2014-11-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1177/1545109712453939;22828983;2012-07-24
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;DERIVED;10.1136/bmjopen-2020-039234;33208326;2020-11-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/j.jhep.2016.09.001;27667367;2017-01-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;;19839502;
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);False;BACKGROUND;10.1016/S0140-6736(16)30856-X;27427455;2016-09-01
NCT01917175;Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire;False;;;;
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;DERIVED;10.1016/S2352-3018(17)30069-3;28566227;2017-09-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/QAD.0b013e32814e6b1c;17545707;2007-06-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/QAD.0b013e3283348944;20010070;2010-01-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/QAD.0b013e32833dec20;20802297;2010-09-24
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/QAD.0b013e328353b066;22441252;2012-07-17
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/QAD.0b013e3282f4243b;18097218;2008-01-11
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1371/journal.pone.0023726;21886816;2011-08-19
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/01.qai.0000180077.59159.f4;16249701;2005-11-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/QAD.0b013e32833db9a1;20802298;2010-09-24
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.3851/IMP2253;22814125;2012-10-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1371/journal.pone.0022003;21811554;2011-07-19
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1097/01.aids.0000218542.08845.b2;16549962;2006-04-04
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.3851/IMP2443;23075703;2012-10-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;False;BACKGROUND;10.1086/589622;18540803;2008-07-15
NCT00445575;Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone;False;;;;
NCT02236832;Study of the Neural Basis of Analogical Reasoning;False;;;;
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;False;PUBMED;10.1186/s12889-023-15710-y;37143029;2023-05-05
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;False;DERIVED;10.1136/bmjopen-2019-030211;31320358;2019-07-01
NCT02125500;Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection;False;;;;
NCT02647632;Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir;False;DERIVED;10.1093/cid/cix916;29077864;2017-10-25
NCT02093754;Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients;False;;;;
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;False;DERIVED;10.1016/j.euf.2017.06.009;28753830;2017-12-01
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;False;DERIVED;10.1111/jsm.12871;25974235;2015-05-01
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;False;PUBMED;10.1016/j.eururo.2015.09.026;26439886;2016-06-01
NCT01463956;Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation;False;;;;
NCT01492985;Lipopeptide Immunisation With GTU-multiHIV Trial;False;DERIVED;10.1128/JVI.02165-20;33568510;2021-04-12
NCT02102737;Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique;False;;;;
NCT01495897;Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study;False;;;;
NCT02408354;Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood;False;DERIVED;10.1186/s13023-017-0713-2;28969699;2017-10-02
NCT03954054;Therapeutic Education for Harm Reduction in People With Alcohol Use Disorder;False;DERIVED;10.1186/s12954-021-00587-0;35012570;2022-01-10
NCT02027233;Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults;False;;;;
NCT00116454;Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis;False;;;;
NCT02014883;Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS;False;DERIVED;10.1136/jnnp-2015-311475;26536893;2015-11-03
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1371/journal.pone.0144317;26636578;2015-12-04
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1371/journal.pone.0071473;23936509;2013-08-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1371/journal.pone.0085516;24465584;2014-01-17
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1371/journal.pone.0074868;24058636;2013-09-18
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.3851/IMP1916;22267473;2012-01-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;SUSPICIOUS;10.1371/journal.ppat.1005774;27509048;2016-08-10
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1194/jlr.M054510;25573889;2015-03-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1097/QAD.0b013e32834dcf61;22008658;2012-01-14
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;False;BACKGROUND;10.1097/QAD.0b013e32835ac8bc;23079802;2013-01-28
NCT01842477;Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing;False;;;;
NCT02976298;Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control;False;;;;
NCT02931097;DBS of the MLR for Gait and Balance Disorders in PD Patients;False;;;;
NCT02101398;Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke;False;;;;
NCT01094899;Abnormal Structure and Bone Density in Diabetes;False;;;;
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);False;DERIVED;10.1002/14651858.CD013359.pub2;32853411;2020-08-27
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);False;DERIVED;10.1016/S1473-3099(22)00668-5;36395782;2023-03-01
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);False;BACKGROUND;10.1186/s12887-021-02576-5;33743621;2021-03-20
NCT02052271;Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation;False;;;;
NCT02906137;Gut-Associated Lymphocyte Trafficking;False;;;;
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;False;RESULT;10.1056/NEJMoa1709481;29539287;2018-03-15
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;False;RESULT;10.1371/journal.pntd.0009048;33657112;2021-03-03
NCT01269632;Cohort of Young Adults Infected With HIV Since Birth or During Childhood;False;;;;
NCT01779752;Vestibular Cortex and TMS;False;;;;
NCT02567071;Natural Microbiota Restoration After C-section Birth;False;;;;
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;False;DERIVED;10.1186/s13195-022-01057-w;36068621;2022-09-06
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;False;PUBMED;10.1371/journal.pone.0295175;38100477;2023-12-15
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;False;DERIVED;10.1159/000515669;33873195;2021-01-01
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;False;DERIVED;10.1212/WNL.0000000000200951;35853750;2022-09-27
NCT04120415;A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02);False;;;;
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);False;DERIVED;10.1542/peds.2018-2065;31455612;2019-09-01
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);False;DERIVED;10.1093/cid/ciw036;26908804;2016-02-07
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);False;DERIVED;10.1016/S2352-3018(17)30206-0;29174612;2018-02-01
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);False;DERIVED;10.1093/cid/ciy897;30689814;2019-01-28
NCT04203628;Evaluation of Four Stool Processing Methods Combined With Xpert MTB/RIF Ultra for Diagnosis of Intrathoracic Paediatric TB (TB-Speed - Stool Processing);False;;;;
NCT05090956;Developpement of 3T MRI Protocol;False;;;;
NCT02214511;Biomarkers of Social Sensitivity in Major Depression;False;;;;
NCT02453061;A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease;False;DERIVED;10.3233/JHD-199003;31381524;2019-08-27
NCT02833961;Diffusion Spectroscopy in Stroke;False;PUBMED;10.1148/radiol.220430;36318030;2023-03-01
NCT02346409;Cerebello-thalamo-cortical Coupling in Essential Tremor;False;;;;
NCT02656407;Intraoperative Functional Ultrasound;False;BACKGROUND;10.1109/TMI.2015.2428634;25955583;2015-11-01
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;False;DERIVED;10.1002/14651858.CD006219.pub4;34611902;2021-10-06
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;False;DERIVED;10.1016/S2352-3018(18)30002-X;29329763;2018-03-01
NCT04392388;Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis;False;PUBMED;10.1093/ije/dyab110;34293141;2021-07-19
NCT04288128;Integrated Functional Evaluation of the Cerebellum;False;PUBMED;10.1001/jamaophthalmol.2024.0001;38421662;2024-04-01
NCT04288128;Integrated Functional Evaluation of the Cerebellum;False;PUBMED;10.1002/mds.29757;38419144;2024-02-28
NCT01534728;Identification of Hepatitis C Virus (HCV) Specific T Cells;False;;;;
NCT01693861;"""Cancersensor"" Chemotherapy";False;;;;
NCT01698411;Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders;False;;;;
NCT02082171;Multidomain Intervention to Prevent Disability in Elders;False;;;;
NCT02150993;First-Line Treatment for HIV-2;False;PUBMED;10.1016/S2352-3018(24)00085-7;38740027;2024-05-01
NCT02157311;4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients;False;DERIVED;10.1093/jac/dkx434;29186458;2017-11-25
NCT04396288;Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response;False;;;;
NCT04409405;Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola);False;PUBMED;10.1016/S1473-3099(23)00552-2;38043556;2024-03-01
NCT02960698;Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study;False;;;;
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1111/add.12149;23421419;2013-03-21
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1001/archinternmed.2010.330;20876416;2010-09-27
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.3851/IMP2699;24166726;2013-02-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1111/j.1365-2893.2010.01417.x;21692942;2011-01-11
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1093/cid/ciu525;25015913;2014-07-11
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1093/cid/ciw379;27317796;2016-06-17
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1097/QAD.0b013e32835763a4;22781224;2012-11-13
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;DERIVED;10.1111/hiv.13127;34212476;2021-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.drugalcdep.2010.09.025;21239121;2011-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1097/QAD.0000000000000218;24499953;2014-05-15
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;DERIVED;10.1016/j.jhep.2020.08.008;32798585;2021-01-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1002/hep.25813;22535683;2012-10-31
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jviromet.2012.01.006;22285372;2012-04-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1371/journal.pone.0050289;23226258;2012-11-30
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jhep.2010.03.007;20493576;2010-08-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1111/dar.12398;27073179;2016-04-13
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1111/j.1360-0443.2011.03608.x;21819472;2011-10-12
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1097/MEG.0000000000000664;27177169;2016-09-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;DERIVED;10.1097/QAI.0000000000001940;30570526;2019-04-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1007/s10620-017-4703-y;28780609;2017-08-05
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1093/cid/civ217;25778750;2015-03-16
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1097/QAD.0000000000000787;26372388;2015-09-10
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1186/1472-6963-12-59;22409788;2012-03-12
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jhep.2017.08.005;28942916;2017-12-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.3851/IMP2419;23052829;2012-10-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1586/17474124.2014.888949;24580042;2014-03-03
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jhep.2011.11.009;22173166;2012-04-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1097/MEG.0000000000000883;28418984;2017-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1111/add.13851;28430385;2017-06-06
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jhep.2011.08.005;21888878;2012-03-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jhep.2017.02.012;28235612;2017-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jcv.2015.10.010;26528903;2015-12-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.jhep.2013.08.014;23978720;2014-01-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1016/j.vaccine.2011.08.125;21920402;2011-11-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1111/hiv.12023;23461846;2013-03-05
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1186/1471-2334-10-303;20969743;2010-10-22
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;False;RESULT;10.1002/hep.28695;27339598;2016-07-29
NCT01880151;Neuroelectrical Biomarkers for Alzheimer's Disease Stages;False;;;;
NCT02172677;The Influence of Collective Schemas on Individual Memory;False;;;;
NCT02721745;Cause and Consequence of Neural Fatigue;False;;;;
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;False;DERIVED;10.1136/jmedgenet-2013-102200;24780882;2014-04-29
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;False;DERIVED;10.1212/WNL.0000000000200257;35264424;2022-05-17
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;False;DERIVED;10.1016/S1474-4422(20)30235-0;32822634;2020-09-01
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;False;DERIVED;10.1016/S1474-4422(13)70104-2;23707147;2013-07-01
NCT05472051;Health and Migration Trajectories of Housekeepers in Bamako;False;;;;
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);False;DERIVED;10.1371/journal.pmed.1001967;26930627;2016-03-01
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);False;RESULT;10.1371/journal.pmed.1002009;27046271;2016-04-05
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);False;BACKGROUND;10.1016/S1473-3099(14)71047-3;25435054;2015-02-01
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);False;DERIVED;10.1371/journal.pntd.0005389;28231247;2017-02-23
NCT04842851;Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle;False;;;;
NCT01688453;Overweight Management and Social Inequalities;False;DERIVED;10.1136/bmjopen-2017-019731;29934380;2018-06-01
NCT01688453;Overweight Management and Social Inequalities;False;DERIVED;10.1016/j.ypmed.2020.106043;32097754;2020-05-01
NCT01688453;Overweight Management and Social Inequalities;False;DERIVED;10.1016/j.conctc.2017.05.010;29696179;2017-09-01
NCT01688453;Overweight Management and Social Inequalities;False;DERIVED;10.1016/j.ypmed.2021.106668;34087324;2021-09-01
NCT01688453;Overweight Management and Social Inequalities;False;PUBMED;10.1017/S136898002200057X;35272723;2022-03-11
NCT01688453;Overweight Management and Social Inequalities;False;DERIVED;10.2196/mhealth.7657;29776897;2018-05-18
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.1093/cid/cix747;29020361;2017-08-19
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.7448/IAS.17.1.18977;24985779;2014-01-01
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.5588/ijtld.17.0016;29297443;2017-12-01
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.1186/s12879-022-07082-2;35093007;2022-01-29
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.1371/journal.pone.0107245;25330161;2014-10-16
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.7448/IAS.16.1.18059;23639243;2013-01-01
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);False;DERIVED;10.1056/NEJMoa1507198;26193126;2015-08-27
NCT02027051;Etude génétique Des Arméniens;False;;;;
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;False;BACKGROUND;10.1016/j.nmd.2010.03.014;20413309;2010-06-01
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;False;BACKGROUND;10.1212/WNL.0000000000000642;24975859;2014-07-29
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;False;PUBMED;10.1016/S2665-9913(20)30280-0;38273639;2021-01-01
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;False;DERIVED;10.3389/fimmu.2021.634508;33717176;2021-02-25
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;False;DERIVED;10.1016/S1473-3099(19)30739-X;32032566;2020-05-01
